Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais.

Roberta Barros Da Silva,Janaina Fonseca Almeida Souza,Josianne Dias Gusmão,Ana Paula Sayuri Sato,Fernanda Penido Matozinhos,Francisco Carlos Felix Lana,Thales Philipe Rodrigues Da Silva

doi:10.11606/s1518-8787.2021055003734

Abstract

ABSTRACTOBJECTIVE To analyze adverse events following immunization (AEFI) against SARS-CoV-2 (covid-19) in the state of Minas Gerais (MG), Brazil.METHODS Epidemiological, descriptive study, with data from e-SUS Notifica (e-SUS Notification) in the state of Minas Gerais from January 20 to March 5, 2021. All suspected cases of AEFI of the covid-19 vaccine in the state were analyzed, totaling 7,305 cases. In this study, we verified the possible correlation between AEFI and the possible immunobiological administered causalities. The variables analyzed for AEFI cases were the immunobiological agent administered (AstraZeneca or Coronavac), the type of event, the evolution of the case, and the time in days since the administration of the immunobiological agent and the onset of symptoms and causality. The incidence rate (IT) was calculated for 100,000 doses applied.RESULTS The occurrence of AEFI as a result of the covid-19 vaccine was frequent (TI: 777.12) in the state. However, only 3% were classified as a severe AEFI, with a 20.85 IT, and 4.71% of them evolved to deaths (8.19 deaths per 100,000 doses applied). Among the deaths analyzed, 84.4% were classified as preexisting conditions caused by factors other than vaccines. Regarding non-serious AEFI, 1.11% occurred by immunization errors (TI: 8.62 EI for every 100 thousand doses applied).CONCLUSION This work encourages the discussion about the importance of recording AEFI related to covid-19 vaccines, demonstrating its safety for the population.

Highlights

Since November 2019, the world has suffered the consequences and transformations caused by a new virus, called SARS-CoV-2, and the related disease, the covid-191
According to the Adverse Events Following Immunization (AEFI) classification, 3% were considered an Serious Adverse Events (SAE) (IT: 20.85 AEFI– EAG for every 100 thousand doses applied), and 4.71% of these events evolved into deaths (IT: 8.19 deaths in every 100 thousand doses applied)
Seven (0.09) of the Immunization errors (IE) cases were associated with adverse events (AE), with an incidence rate (IT) of 0.74 per 100,000 doses

Summary

Introduction

Since November 2019, the world has suffered the consequences and transformations caused by a new virus, called SARS-CoV-2, and the related disease, the covid-191. Nowadays we live a pandemic[2,3] or syndemic[4] situation given its rapid spread[1,5] and the occurrence of new variants[6] The spread of this virus has been rapid in several countries[1,5]. A study with 250,000 cases of covid-19 in Brazil showed a wide distribution of the disease in all regions of the country, resulting in a high overall burden of the disease[9]. In this epidemiological context, a new covid-19 vaccine will need to cover at least 55% of the population to provide collective immunity, reaching 85% depending on the country[10]

Methods

Results

Discussion

Conclusion